Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Company

Beijing Cancer Prevention & Treatment Society

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 12, 2026 · PHASE 2 TRIAL

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib

ClinicalTrials.gov

Phase 2 randomized trial with planned PFS endpoint at ~30 months; recruitment completed but results not yet reported in this registry record.

PreliminaryNCT04769388 Pemetrexed/Carboplatin Osimertinib

Reported

Sample size80

PhasePhase 2

Primary outcome measureProgression-free survival (PFS) by investig…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support